Litigation Details for City of Providence, Rhode Island v. AbbVie Inc. (S.D.N.Y. 2020)
✉ Email this page to a colleague
City of Providence, Rhode Island v. AbbVie Inc. (S.D.N.Y. 2020)
| Docket | ⤷ Sign Up | Date Filed | 2020-07-17 |
| Court | District Court, S.D. New York | Date Terminated | |
| Cause | 15:1 Antitrust Litigation (Monopolizing Trade) | Assigned To | |
| Jury Demand | Plaintiff | Referred To | |
| Patents | 6,545,040 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in City of Providence, Rhode Island v. AbbVie Inc.
The small molecule drug covered by the patent cited in this case is ⤷ Sign Up .
Details for City of Providence, Rhode Island v. AbbVie Inc. (S.D.N.Y. 2020)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2020-10-13 | 30 | Memorandum & Opinion | sued them for infringement of U.S. Patent No. 6,545,040 (the “‘040 patent”). Id. ¶ 5. Each generic company…companies’ position in the patent litigation was very strong. Id. ¶ 7. An earlier patent had disclosed a nebivolol…their products did not infringe the ‘040 patent, or the ‘040 patent was invalid. Nonetheless, between…In June 2015, the last patent protecting Bystolic (other than the ‘040 patent) expired. Id. ¶ 7. It is…that its generic would not infringe the asserted patent claims or the claims were invalid. The | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
